Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 02

270P - Influence of neoadjuvant chemotherapy-induced short-term amenorrhea on pathologic response and treatment outcome in ER+HER2- breast cancer

Date

21 Oct 2023

Session

Poster session 02

Topics

Tumour Site

Breast Cancer

Presenters

Seung Eun Lee

Citation

Annals of Oncology (2023) 34 (suppl_2): S278-S324. 10.1016/S0923-7534(23)01258-9

Authors

S.E. Lee1, Y. Kook2, B. Seung Ho2, S. Moon1, J. Kim1, M.J. Kim1, S.J. Bae2, J. Jeong2, S.B. Lee3, S.G. Ahn2

Author affiliations

  • 1 Department Of General Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 06273 - Seoul/KR
  • 2 Department Of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 06273 - Seoul/KR
  • 3 Department Of Surgery, Asan Medical Center - University of Ulsan, 138-931 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 270P

Background

Premenopausal women experience temporary ovarian function suppression (OFS) during the period of chemotherapy. In ER+ breast cancer, chemotherapy-induced temporary OFS may offer anti-estrogenic effect in addition to direct cytotoxic anti-tumor effect. It is unclear whether anti-estrogenic effect by temporary OFS during neo-adjuvant chemotherapy (NAC) enhance anti-tumor effect. Based on pathologic complete response (pCR) and complete cell-cycle arrest (CCCA), we compared pathologic response and outcomes between younger and older patients with ER+HER2- breast cancer treated with NAC.

Methods

Between 2007 January and 2021 June, we retrospectively identified 1,178 patients with ER+HER2- breast cancer who underwent NAC in the Gangnam Severance Hospital and the Asan Medical Center. We compared the pCR rate according to age under 45 and over 55 and investigated durations of NAC, clinical stage, and Ki-67. Pathologic complete response was defined as no invasive residual disease in both breast and axillae. In addition, we collected available Ki67 expression in surgical specimen after NAC. We defined low Ki67 with a cutoff of 2.7%. The recurrence-free survival was evaluated in patients with post-NAC Ki67.

Results

In all 1,178 patients, the pCR rate was 1.9% (22/1,178). The rate was 1.4% (8/552) in younger patients (age ≤45), whereas it was 3.6% (9/250) in older patients (age ≥55) (p= 0.063, Chi-square test). In 524 patients who received NAC consisting of anthracyclines and taxanes with a duration of NAC longer than 6 months, the pCR rate did not differ between the younger patients and the older (2.1%, 5/243 vs. 2.8%, 3/106; p= 0.703). In patients with post-NAC Ki67, the CCCA rates were 66.2% (307/464) in the younger and 39.8% (86/216) in the older, respectively (p<0.001). Survival analyses showed that, compared to patients with CCCA, those without CCCA experienced a significant decrease in RFS in both younger and older women.

Conclusions

While short-term OFS resulting from NAC led to a higher rate of CCCA in premenopausal women, younger women had notably poorer survival outcomes compared to older women. Among premenopausal women, achieving CCCA was associated with a slight improvement in treatment outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Gangnam Severance Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.